Sapphire Star Partners LP lowered its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,840 shares of the medical research company’s stock after selling 586 shares during the period. Amgen accounts for 4.6% of Sapphire Star Partners LP’s investment portfolio, making the stock its 2nd biggest holding. Sapphire Star Partners LP’s holdings in Amgen were worth $3,473,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of AMGN. Annex Advisory Services LLC increased its position in shares of Amgen by 7.2% in the fourth quarter. Annex Advisory Services LLC now owns 10,157 shares of the medical research company’s stock valued at $1,977,000 after acquiring an additional 678 shares during the period. Premier Fund Managers Ltd boosted its stake in Amgen by 11.6% during the fourth quarter. Premier Fund Managers Ltd now owns 25,141 shares of the medical research company’s stock worth $4,795,000 after acquiring an additional 2,608 shares in the last quarter. Bahl & Gaynor Inc. boosted its stake in Amgen by 41.6% during the fourth quarter. Bahl & Gaynor Inc. now owns 1,336,055 shares of the medical research company’s stock worth $260,089,000 after acquiring an additional 392,493 shares in the last quarter. Penobscot Investment Management Company Inc. boosted its stake in Amgen by 2.9% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 28,636 shares of the medical research company’s stock worth $5,574,000 after acquiring an additional 810 shares in the last quarter. Finally, Sarasin & Partners LLP boosted its stake in Amgen by 0.8% during the fourth quarter. Sarasin & Partners LLP now owns 862,892 shares of the medical research company’s stock worth $167,979,000 after acquiring an additional 6,960 shares in the last quarter. Institutional investors own 80.04% of the company’s stock.
In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total transaction of $377,760.00. Following the completion of the transaction, the director now owns 14,988 shares in the company, valued at $2,830,933.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 6,000 shares of company stock valued at $1,144,120. 0.27% of the stock is owned by company insiders.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $5.88 billion. During the same period in the prior year, the company posted $2.89 earnings per share. On average, research analysts expect that Amgen, Inc. will post 13.82 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.20%. Amgen’s dividend payout ratio is 40.28%.
AMGN has been the topic of several research reports. Cowen reissued a “buy” rating and set a $234.00 price objective on shares of Amgen in a research note on Tuesday, February 26th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, January 14th. Goldman Sachs Group reiterated a “buy” rating and issued a $232.00 target price on shares of Amgen in a research note on Thursday, January 17th. Mizuho reiterated a “buy” rating and issued a $211.00 target price on shares of Amgen in a research note on Wednesday, February 13th. Finally, BidaskClub downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 29th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $209.11.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.